In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators

Hormone Research in Paediatrics

Volumn 48, Issue 4, 1997, Pages 155-163

  Mitlak, Bruce H ^a   Cohen, Fredric J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antiestrogen; Estrogen; Osteoporosis; Raloxifene; SERM

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN;

FEMALE; GENE ACTIVATION; HORMONE ACTION; HORMONE SUBSTITUTION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TARGET ORGAN;

EID: 0030775052     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000185507     Document Type: Article

References (66)

1. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, HennekensCH: Menopause and the risk of heart disease in women, N Engl J Med 1987;316:1105-1110.
2. Kiel DP, Felson DT, Anderson JJ, Wilson PN, Moskowitz MA: Hip fracture and the use of estrogen in post menopausal women: The Framingham study, N Engl J Med 1987:317: 1169-1174.
3. Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of Alzheimer's disease in women, Am J Epidemol 1994;140:256-261.
4. US Congress, Office of Technology Assessment, Effcctivencsss and Costs of Osteoporosis Screening and Hormone Replacement Therapy: Washington, US Government Printing Office, 1995.
5. Lindsay R, Bush TL, Grady D, Spcroff L, Lobo RA: Therapeutic controversy: Estrogen replacement in the menopause, J Clin Endocrinol Mctab 1996;81:3829-3838.
6. Women's Health Initiative Study Group: Protocol for the clinical trial and observational study, WHI manuals, vol 1, Seattle, Fred Hutchinson Cancer Research Center, 1995.
7. The Writing Group for the PEPI Trial: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial, JAMA 1996; 276:1389-1396.
8. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin intervention (PEPI) trial, JAMA 1995:273: 199-208.
9. Utian WH, Schiff I: NAMS-Gallup survey on women's knowledge, information sources, and altitudes to menopause and hormone replacement therapy, Menopause 1994:1:39-48.
10. Archer DF, Pickar JH, Bottiglioni F: Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate, Obstct Gynecol 1994:83:686-692.
11. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens CH, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women, N Engl J Med 1995: 332:1589-1593.
12. Grady D, Rubin SM, Pctitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in a post-menopausal woman, Ann Intern Med 1992:117:1016-1037.
13. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J: Cloning of a novel estrogen receptor expressed in rat prostate and ovary, Proc Natl Acad Sei USA 1996:93:5925-5930.
14. Mossclman S, Polman J, Dijkcma R: ERß identification and characterization of a novel human estrogen receptor, FEBS Lett 1996:392: 49-53.
15. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, De-mcts DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer, N Engl J Med 1992:326:852-856.
16. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, Dcmets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer, J Natl Cancer Inst 1990:82:1327-1332.
17. Adashi EY: Clomiphene citrate: Mcchanism(s) and site(s) of action: A hypothesis revisited, Fcrtil Steril 1984;61:265-268.
18. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatcment of breast cancer in women, EndocrRev 1990:11:221-265.
19. Hayes DF, Van Zyl JA, Hacking A, Gocdhals L, Bczwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfeldcr J: Randomized comparison of tamoxifen and two separate doses of torcmifcnc in postmenopausal patients with metastatic breast cancer, J Clin Oncol 1995;13:2556-2566.
20. Draper MW, Flowers DE, Huster WJ, Ncild JA, Harper KD, Amaud C: A controlled trial of raloxifene (LYI39481) HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women, J Bone Miner Res 1996:1 1:835-842.
21. Grese TA, Sluka JP, Bryant HU, Cole HW, Kim JR, Magee DE, Rowley ER, Sato M: Ben-zopyran selective estrogen receptor modulators (SERMs): pharmacological effects and structural correlation with raloxifene, Bioorg Med Chem Lett 1996;6:903-908.
22. Kamboj VP, Ray S, Dhawan BN: Ccntchro-man, Drugs Today 1992:28:227-232.
23. Grese TA, Cole HW, Magee DE, Phillips DL, Shetler PK, Short LI, Glasebrook AL, Bryant HU: Conversion of the phytoestrogen coumcs-trol into a selective estrogen receptor modulator (SERM) by attachment of an amine-containing sidechain, Bioorg Med Chem Lett 1996:6:2683-2686.
24. Wakcling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential, Cancer Res 1991:51:3867-3873.
25. Howell A, DeFriend DJ, Robertson JF, Blarney RW, Anderson L, Anderson E, Sutcliffe FA, Walton P: Pharmacokinetics, phamacological and anti-tumour effects of the specific antioestrogen IC1 182780 in women with advanced breast cancer, Br J Cancer 1996:74:300-308.
26. Katzcnellenbogcn BS, Montano MM, Lc Goff P, Schodin DJ, Kraus WL, Bhardwaj B, Fuji-moto N: Antiestrogens: Mechanisms and actions in target cells, J Steroid Biochem Mol Biol 1995;53:387-393.
27. Coilctta AA, Benson JR, Baum M: Alternative mechanisms of action of anti-ocstrogcns, Breast Cancer Res Treat 1994:31:5-9.
28. Katzenellenbogen JA, O'Malley BW, Katzcnel-lenbogen BS: Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones, Mol Endocrinol 1996:10:119-131.
29. Beale M, Sanchcz-Pachcco A: Interaction of steroid hormone receptors with the transcription initiation complex, Endocr Rev 1996:17: 587-609.
30. Berry M, Metzger D, C'hambon P: Role of the two activating domains of the oestrogen receptor in the ccll-tvpe and promoter-contcxt dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifcn, EMBO J 1990:9:2811 - 2818.
31. Danielian PS, White R, Lees JA, Parker MG: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors, EMBO J 1992; 11:1025-1033.
32. Webb P, Lopez GN, Uht RM, Kushncr PJ: Tamoxifen activation of the estrogen receptor/ AP-1 pathway: Potential origin for the cell-specific estrogen like effects of antiestrogens, Mol Endocrinol 1995;9:443-456.
33. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW: Analysis of estrogen receptor function in vitro reveals three distinct classes of antieslrogens, Mol Endocrinol 1995; 9:659-669.
34. Yang NN, Vcnugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17bcta-cstradiol and raloxifene, Science 1996:273: 1222-1225.
35. Elgon MG, Zou A, Marschkc KB, Allegretto EA: Estrogen and estrogen receptor antagonists stimulate transcription from the human retino-ic acid reccptor-alphal promoter via a novel sequence, Mol Endocrinol 1996:10:477-487.
36. Sato M, Glasebrook AL, Bryant HU: Raloxifene: a selective estrogen receptor modulator, J Bone Miner Metab 1994; 12(suppl 2):S9-S20.
37. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Ter-mine JD, Bryant HU: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovaricctomized rats, J Clin Invest 1994: 93:63-69.
38. Cole MP, Jones CT, Todd ID: A new anti-oes-trogcnic agent in late breast cancer, An early clinical appraisal of ICI46474. Br J Cancer 1971:25:270-275.
39. Jaiycsimi IA, Buzdar AU, Decker DA, Horto-bagyi GN: Use of tamoxifen for breast cancer: Twenty-eight years later, J Clin Oncol 1995:13: 513-529.
40. Ward RL, Morgan G, Dailey D, Kelly PJ: Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women, Bone Miner 1993:22:87-94.
41. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmcgaard SN, Transbol I, Mouridsen HT, Transbol I: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study, J Clin Oncol 1994: 12:992-997.
42. Wright CD, Garrahan NJ, Stanton M, Gazet JC, Mansell RE, Compston JE: Effect of longterm tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer, J Bone Miner Res 1994:9:153- 159.
43. Love RR, Barden US, Mazcss RB, Epstein S, Chappell RJ: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years, Arch Intern Med 1994; 154:2585-2588
44. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR: The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women, Am J Med 1995;99:636-641.
45. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women, J Clin Oncol 1996:14:78- 84.
46. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Trclcavcn JG, Singh R: The effect of tamoxifen and hormone replacement therapy on scrum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study, Ann Oncol 1996:7:671-675.
47. Gotfredscn A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer, Cancer 1984;53:853-857.
48. Boccardo F, Bruzzi P, Rubagotti A, Nicolo G, Rosso R: Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients, Oncology 1981:38:281-285.
49. Friedl A, Jordan VC: What do we know and what don’t we know about tamoxifen in the human uterus, Breast Cancer Res Treat 1994; 31:27-39.
50. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment, CancerTreal Rep 1984.68:887-889.
51. Daly E, Vcsscv MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy, Lancet 1996;348:977-980.
52. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oeslrogens, Lancet 1996;348:981-983.
53. Grodstcin F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Spcizer FE, Willett WC, Hennckens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women, Lancet 1996:348:983-987.
54. Fischer B, Dignam J, Bryant J, Dieillis A, Wiekerham DL, Wolmark N, Costanlino J, Redmond C, Fisher ER, Bowman DM, Des-chenes L, Dimitrov NV, Margolese RG, Robi-doux A, Shibata H, Terz J, Paterson AHG, Feldman Ml, Farrar W, Evans J, Licklev HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumors, J Natl Cancer Inst 1996;88:1529-1542.
55. Wakcling AE, Valcaccia B, Newboull E, Green LR: Non-steroidal antioestrogens: Receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells, J Steroid Biochcm 1984:20:111-120.
56. Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, kcoxifcnc (LY156758), on growth of carcinogen-induced mammarv tumors and on LH and prolactin levels, Life Sci 1983:32:2869-2875.
57. Buzdar AU, Marcus C, Holmes F, Hug V, Hor-tobagyiG: Phase II evaluation of LY 156758 in metastatic breast cancer, Oncology 1988:45: 344-345.
58. Turner CH, Sato M, Bryant HU: Raloxifene preserves bone strength and bone mass in ovariectomized rats, Endocrinology 1994:135: 2001-2005.
59. Evans G, Bryant HU, Magee D, Sato M, Turner RT: The effects of raloxifene on tibia histo-morphometry in ovariectomized rats, Endocrinology 1994:134:2283-2288.
60. Draper MW, Flowers DE, Huster WJ, Ncild JA: Effects of raloxifene (LY 139481 HCI) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women; in Christiansen C, Riis B (eds): Proceedings 1993. Fourth International Symposium on Osteoporosis and Consensus Development Conference, Alborg, Handelstrykkeriet Aalborg ApS, 1993. pp 119-121.
61. Heaney RP, Draper MW: Raloxifene mimics estrogen in human bone remodeling kinetics (abstract), J Bone Miner Res 1996:1 586.
62. Rauschning W, Pritchard KL: Droloxifenc, a new anticstrogen: Its role in metastatic breast cancer, Breast Cancer Res Treat 1994:31:83-94.
63. Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettinen TA: Tamoxifen and toremifenc lower scrum cholesterol by inhibition of delta 8-cholcstcnol conversion to latho-sterol in women with breast cancer, J Clin Oncol 1995; 13:2900-2905.
64. Cootnbcs RC, Haynes BP, Dowsctt M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R, Jarman M: Idoxifcne: Report of a phase I study in patients with metastatic breast cancer, Cancer Res 1995:55:1070-1074.
65. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I: Antiatherogenic effects of adjuvant anlicstrogens: A randomized trial comparing the effects of tamoxifen and toremifenc on plasma lipid levels in postmenopausal women with node-positive breast cancer, J Clin Oncol 1996:14:429-433.
66. Tomas E, Kauppila A, Blanco G, Apaja-Sark-kincn M, Laatikaincn T: Comparison between the eTects of tamoxifen and toremifenc on the uterus in postmenopausal breast cancer patients, Gynecol Oncol 1995:59:261 -266